Press Releases Press Releases Year None202120202019201820172016201520142013201120102009200820072005 June 7, 2021 CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology PDF Version May 26, 2021 Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences PDF Version May 10, 2021 Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update PDF Version May 5, 2021 Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences PDF Version May 4, 2021 Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast PDF Version May 3, 2021 Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression PDF Version April 22, 2021 Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting PDF Version April 20, 2021 Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting PDF Version April 12, 2021 Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting PDF Version February 25, 2021 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update PDF Version Pagination Current page 1 Page 2 Next page next › Last page last »
June 7, 2021 CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology PDF Version
May 10, 2021 Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update PDF Version
May 4, 2021 Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast PDF Version
May 3, 2021 Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression PDF Version
April 22, 2021 Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting PDF Version
April 20, 2021 Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting PDF Version
April 12, 2021 Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting PDF Version
February 25, 2021 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update PDF Version
